SSTR5 is also expressed in abundance on somatotropinomas (22), providing rationale for the use of pasireotide in patients uncontrolled on SSTR2-preferential first-generation somatostatin analogues. This evidence concerns the gene SSTR2 and growth hormone-producing pituitary gland neoplasm.